Physician CME

In this brief 15-minute activity, you will:

– Follow the case of a patient who presents with foot drop and no other medical conditions
– Choose optimal management approaches by answering nongraded questions within the activity (answers are collected for informational purposes only and used to assess the effectiveness of this educational activity)
– See how your answers compare with those of your peers
– View video clips providing expert insights

In this 15-minute activity, meet 2 patients with arm pain, one of whom also presents with neck pain. How would you manage these patients? This accredited activity uses an interactive, quiz-driven microlearning format to explore clinical case scenarios with targeted questions, allowing clinicians to quickly assess their knowledge. Clinicians can compare their responses with those of their peers and receive expert guidance through video commentary.

This accredited activity reviews advancements in lung transplant surgery, with a focus on robotic lung transplant and ex vivo lung perfusion.

This 30-minute Symposium from the 2025 Fall Clinical Dermatology Conference for PAs and NPs explores how to personalize psoriasis management and improve treatment selection based on patient specific history.

“With biologics we have gotten more specific. Before we had this big sweeping sword and now we have these precise, tiny knives. That is where we are at with going from previous agents to IL-23 and IL-17 blockers.” – Dr. Harrison Nguyen.

This activity is supported by educational grants from AbbVie, Johnson & Johnson and Ortho Dermatologics, and SUN Pharmaceutical Industries, Ltd.

Recent advancements in refractive surgery techniques and technologies continue to evolve, offering expanded options for managing patients with refractive errors. Lens-based refractive surgery presents an alternative to traditional laser-based approaches, providing a broader range of correctable refractive errors and enabling personalized treatment plans tailored to each patient’s unique needs. In this CE monograph, experts will explore the current role of lens-based refractive surgery for myopia correction, compare it with traditional laser-based refractive procedures, and share valuable clinical insights on selecting the most suitable patients for lens-based versus laser-based refractive surgery in the context of myopia treatment.

In this online, self-learning activity:

Thalassemias belong to a group of recessively inherited blood disorders characterized by little or no hemoglobin production and chronic anemia of varying severity. Alpha thalassemia (AT) is most commonly found in people of Mediterranean, Middle Eastern, Asian, and North African descent. Worldwide, 5% of people are AT carriers, with a much higher prevalence in certain regions (e.g., up to 23% in Southeast Asia). AT is typically caused by deletions of one or more α-globin genes, leading to reduced or abolished α-globin production; non-deletional forms of AT can also occur and are generally more severe. The loss of functional α-globin disrupts the globin chain equilibrium, leading to excess γ- and β-globin chain formation and causing ineffective erythropoiesis. Patients with both deletional and non-deletional types of AT can develop various clinical complications, such as iron overload, gallstones, impaired liver function, osteoporosis, and elevated uric acid levels. Cardiopulmonary and skeletal deformities are common in patients from countries in the Western hemisphere who have elevated ferritin, while infections are the leading complication and cause of death in patients who live in countries in the Eastern hemisphere and have transfusion-dependent thalassemia.

In this online, self-learning activity:

Hemophilia is a genetic disease caused by mutation of one of the genes for coagulation proteins leading to dangerous, uncontrolled bleeding. In hemophilia B, a mutation in the gene for factor IX (FIX) leads to an endogenous deficiency in the clotting factor. The incidence of hemophilia B is the same across race and ethnic groups, affecting approximately 1 out of every 30,000 male births.

This CME program is designed to enhance neurologists’ understanding and management of generalized myasthenia gravis (gMG). Participants will explore how comprehensive assessment of disease burden can inform clinical decision-making and improve individualized care. The program will also examine the pathophysiology of gMG, emphasizing how this guides treatment selection. The limitations of current standard-of-care therapies will also be explored. Participants will review the latest clinical evidence surrounding neonatal Fc receptor (FcRn) inhibitors, including their role in addressing underlying disease processes and supporting long-term management strategies. By integrating all of these insights, neurologists will be better equipped to optimize patient outcomes and achieve sustained disease control in individuals with gMG.

Primary biliary cholangitis (PBC) causes chronic inflammation and progressive destruction of the bile ducts, resulting in cholestatic pruritus—a severe internal itch that scratching cannot relieve. Patients with PBC experience substantial impacts to their quality of life and face significant disparities in care across demographic, geographic, and socioeconomic factors. Adoption of standardized assessments and monitoring procedures can lead to earlier, more accurate diagnoses and personalized treatment plans across this patient population. Standard first-line treatment for this condition is ursodeoxycholic acid (UDCA) and, as of summer 2024, 2 novel peroxisome proliferator-activated receptor (PPAR) agonists have been approved for use in patients with inadequate response to UDCA.

These currently available treatments have demonstrated efficacy in improving liver function tests and reducing fibrosis progression, but do not target symptom management. Clinical investigations into novel therapies for managing PBC include additional PPAR agonists and fibroblast growth factor analogues, which have shown promise in improving liver function and reducing inflammation, as well as an ileal bile acid transport inhibitor, which has demonstrated efficacy in relieving cholestatic pruritus. In this CE activity, experts in the field detail the patient burden associated with PBC and the disparities in its care; evaluate processes and procedures that improve the assessment of patients with PBC; and distinguish current and emerging therapies for PBC symptom management regarding their targets and mechanisms of action.

Second-generation anti-vascular endothelial growth factor (VEGF) therapies with longer duration of action offer patients with neovascular age-related macular degeneration (nAMD) the potential for optimized visual and anatomical outcomes with extended intervals between doses. However, incorporating these newer therapies into individualized management protocols can be challenging. In this CE activity, Drs. Christina Weng and Nathan Steinle discuss individualized management options for a community-based nAMD patient case, offering insights into best practices for durable anti-VEGF therapeutic options through analysis of the latest clinical evidence and patient characteristics and preferences.

Second-generation anti-vascular endothelial growth factor (VEGF) therapies provide patients with diabetic macular edema (DME) and diabetic retinopathy (DR) the opportunity for improved visual and anatomical outcomes with less-frequent dosing. However, managing patients with DME/DR can be complex, requiring collaborative-care approaches to offer personalized treatment options and address care disparities. In this CE activity, Drs. Christina Weng and Dennis Marcus discuss collaborative care approaches and individualized management options for a community-based DME patient case, offering clinical insights for the optimal incorporation of durable anti-VEGF therapeutic options into management protocols through analysis of the latest clinical evidence and patient characteristics and preferences.

This CME activity discusses the diagnosis and treatment of ATTR-CM and highlights key updates on ATTR-CM treatment from the ACC 2025 annual meeting.

This CME activity discusses the diagnosis and treatment of ATTR-CM and highlights key updates on ATTR-CM treatment presented at the HFSA Annual Scientific Meeting 2025 and AHA Scientific Sessions 2025.

In this #CME #MedX, get the latest guidance on managing hypertrophic cardiomyopathy (HCM), including confirming an obstructive HCM (oHCM) diagnosis, integrating recent clinical information on cardiac myosin inhibitor treatments, and addressing patients’ concerns and questions about living with HCM.

In this MedX activity, Robert Haddad, MD, explores the latest clinical data for emerging novel therapies for recurrent/metastatic head and neck squamous cell carcinoma with an emphasis on results presented at ESMO 2025.

In this CME activity, discover the latest information on investigational factor XI/XIa inhibitors, including results from completed clinical trials and news about ongoing clinical trials, to explore their potential role in managing stroke risk in patients with atrial fibrillation (AF).

In this online, self-learning activity:

Chronic lymphocytic leukemia (CLL) is a disease in which leukemic cells accumulate in the peripheral blood, bone marrow, and lymphatic tissue. Elderly patients comprise the vast majority of those diagnosed with CLL with a mean patient age of 72 years. There are over 23,000 cases in the U.S. per year, with an annual mortality rate in excess of 4,400. CLL may have an indolent disease course and go undetected for some time. Patients may present clinically with a range of constitutional symptoms usually range from lymphadenopathy (the most common), night sweats, weight loss, weakness, and fever. Staging systems take into account a variety of factors, including lymphadenopathy, splenomegaly, hepatomegaly, and the presence and severity of cytopenias, while a patient’s prognosis is impacted by cytogenetic abnormalities and earlier progression of disease. Both the presentation and progression of CLL vary between patients, although patients with very-high-risk disease have a median survival of 19 months and a five-year overall survival of less than 24%.

In this accredited CME activity, meet a patient who presents with right lower extremity pain with exertion. What will your next steps be in the management of this patient? This activity will discuss modifiable cardiovascular risk factors, sex-specific markers of risk, and management of diabetes in the presence of cardiovascular disease. The activity starts with an introduction to a patient scenario, followed by a case-related question and brief answer explanations.

Guideline updates and recommendations are key patient management tools for cardiac care. This accredited educational activity is designed for primary care physicians and presents a curated series of posts and data centered on the updated AHA/ACC/HFSA guidelines for the management of heart failure. It provides a comprehensive review of the latest evidence-based recommendations, critically examines the clinical trial data behind these guidelines, and underscores the clinical significance of early initiation of guideline-directed medical therapies and timely specialist referral to optimize patient outcomes in heart failure care.

Sacroiliac joint pain is common, accounting for 10% to 38% of cases of chronic low back pain. In this educational activity, learn about the diagnosis and management of patients with sacroiliac pain, including when to consider minimally invasive robotic surgery.